Medivation (NASDAQ:MDVN), According to the latest information the short interest in Medivation, Inc. plummeted by 18.4% or 673,367 shares. The final shorts are 1.8% of the total floated shares. The positions dropped from 3,663,013 shares on May 31,2016 to 2,989,646 on June 15,2016. According to the per-day average trading of 1,765,157 shares, the days to cover are 2. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Medivation (NASDAQ:MDVN): The stock opened at $58.00 on Friday but the bulls could not build on the opening and the stock topped out at $58.42 for the day. The stock traded down to $56.87 during the day, due to lack of any buying support eventually closed down at $56.95 with a loss of -3.90% for the day. The stock had closed at $59.26 on the previous day. The total traded volume was 6,065,855 shares.
The company shares have rallied 3.45% from its 1 Year high price. On May 10, 2016, the shares registered one year high at $62.94 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $60.34 and the 200 Day Moving Average price is recorded at $46.14.
Medivation (NASDAQ:MDVN) has tumbled 4.01% during the past week and has dropped 6.07% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2.42%. Medivation (NASDAQ:MDVN) has underperformed the index by 3.23% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.